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Background: The optimal choice of cytotoxic drugs for intraperitoneal chemotherapy (IPC) in conjunction with
cytoreductive surgery (CRS) for treatment of peritoneal carcinomatosis (PC) is poorly defined. We investigated drug
sensitivity ex vivo in patient samples of various PC tumor types and correlated clinical outcome to drug sensitivity
within the subset of PC from colorectal cancer (CRC).
Methods: PC tissue samples (n = 174) from mesothelioma, pseudomyxoma peritonei (PMP), ovarian cancer, CRC or
appendix cancer were analyzed ex vivo for sensitivity to oxaliplatin, cisplatin, mitomycin C, melphalan, irinotecan,
docetaxel, doxorubicin and 5-FU. Clinicopathological variables and outcome data were collected for the CRC subset.
Results: Mesothelioma and ovarian cancer were generally more drug sensitive than CRC, appendix cancer and
PMP. Oxaliplatin showed the most favorable ratio between achievable IPC concentration and ex vivo drug
sensitivity. Drug sensitivity in CRC varied considerably between individual samples. Ex vivo drug sensitivity did not
obviously correlate to time-to-progression (TTP) in individual patients.
Conclusions: Drug-sensitivity varies considerably between PC diagnoses and individual patients arguing for
individualized therapy in IPC rather than standard diagnosis-specific therapy. However, in the current paradigm of
treatment according to diagnosis, oxaliplatin is seemingly the preferred drug for IPC from a drug sensitivity and
concentration perspective. In the CRC subset, analysis of correlation between ex vivo drug sensitivity and TTP was
inconclusive due to the heterogeneous nature of the data.
Keywords: Chemotherapy resistance, Cytoreductive surgery, Drug sensitivity, Fluorometric microculture cytotoxicity
assay, Hyperthermic intraperitoneal chemotherapy, Peritoneal carcinomatosisBackground
Peritoneal carcinomatosis (PC) was previously regarded as an
incurable form of malignant disease with a poor prognosis,
and the intention of treatment was palliative. However, ag-
gressive cytoreductive surgery (CRS) followed by intraperito-
neal chemotherapy (IPC), may produce prolonged long-term
survival and even cure [1-5]. The most recent development
in the management of PC is the intraoperative use of hyper-
thermic intraperitoneal chemotherapy (HIPEC) [6].
The individual therapeutic impact of cytoreductive
surgery and IPC, respectively, has not been sufficiently* Correspondence: peter.cashin@surgsci.uu.se
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reproduction in any medium, provided the orclarified [7]. In ovarian cancer, IPC is more active than
the corresponding drug given iv and in gastric cancer, IPC
has been shown to add benefit to CRS and systemic
chemotherapy [8,9]. In PC from colorectal cancer (CRC),
the role of IPC when added to CRS has not been elucidated
in randomized trials but cytoreductive surgery, IPC,
and systemic chemotherapy is favorable compared with
systemic chemotherapy and palliative surgery [10]. An
experimental study in the rat demonstrated a significant in-
crease in survival when adding IPC to cytoreductive surgery
vs. cytoreductive surgery alone [11].
The selection of drugs for IPC has mostly been based on
the experience from systemic administration, pharmacody-
namic properties, hyperthermic enhancement, technical
feasibility, pharmacokinetics and tolerance [12,13]. The IPCLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Number of patient samples included in the analyses
CELL TYPE TREATED (n) UNTREATED (n) TOTAL (n)
Pseudomyxoma 24 48 72
Mesothelioma 7 8 15
Appendix 11 5 16
Colorectal 39 13 52
Ovarian 15 4 19
AML 6 6 12
CLL 0 12 12
MNC NA NA 44
Treated/untreated refers to whether the patients sampled had previously
received chemotherapy (treated) or not (untreated).
Abbreviations: AML acute myeloblastic leukemia, CLL chronic lymphocytic
leukemia, MNC mononuclear cells, NA not applicable.
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differences in drug sensitivity in the different tumor types
or differences in tumor cell sensitivity between individual
patients. Currently, cisplatin, doxorubicin, mitomycin C,
oxaliplatin and irinotecan, as single drugs or sometimes
combined, are the most commonly used drugs for HIPEC
treatment [14-18]. A more differential approach to drug
selection for the IPC in PC might provide more benefit
from this part of the treatment of PC.
With this background, we investigated ex vivo the activity
of standard cytotoxic drugs in IPC on tumor cells derived
from patients with various types of PC using an ex vivo
model reflecting clinical drug activity. The aims were to in-
vestigate differences in drug sensitivity between various PC
tumor types and individual patient samples and to investi-
gate if differences in clinical outcome are associated with
drug sensitivity within the subset of CRC.
Methods
Tumor sampling and cell preparation
Tumor sampling of patients with PC from appendix cancer,
CRC, pseudomyxoma peritonei (PMP), ovarian cancer,
or mesothelioma was performed intraoperatively during
cytoreductive surgery prior to IPC. Leukemia sampling
was by vein puncture at routine blood sampling and
mononuclear cells (MNCs) were prepared from buffy
coats from healthy blood donors. Tumour sampling and
data collection was based on patient informed consent as
approved by the regional ethical committee in Uppsala
(Uppsala Etiknämnd: Dnr 2007/237).
Tumor cells from solid tumor tissue were prepared
by collagenase digestion as described [19]. Leukemia cells
and MNCs were collected by Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden) gradient centrifugation [20].
The cells obtained from the solid tumors were single
cells or small cell clusters with ≥ 90% viability and with
less than 30% contaminating non-malignant cells, as
judged by morphological examinations of May-Grünwald-
Giemsa-stained cytocentrifugate preparations. Approxi-
mately 85% of all samples obtained fulfilled the criteria
for a successful assay (see below) and were included in
this study. The numbers and types of samples included
are detailed in Table 1.
Drugs and measurement of drug sensitivity ex vivo
The cytotoxic drugs melphalan (Mel; GlaxoSmithKline,
Stockholm, Sweden), cisplatin (Cisp; Bristol-Myers
Squibb, Stockholm, Sweden), oxaliplatin (Oxali; Sanofi-
Synthelabo, Stockholm, Sweden), doxorubicin (Dox; Pfizer,
Stockholm, Sweden), docetaxel (Doce), 5-fluorouracil (5FU;
Roche, Stockholm, Sweden), mitomycin C (MitC; Bristol-
Myers Squibb) and irinotecan (Irino; Pfizer) were from
commercially available clinical preparations. The drugs
were tested at three 10-fold dilutions from the maximalconcentration (μM) of 100 for Mel, 100 for Cisp, 100 for
Oxali, 10 for Dox, 100 for Doce, 1000 for 5-FU, 100 for
MitC and 1000 for Irino. Irino shows relevant activity
ex vivo under conditions of the FMCA despite being
considered as a prodrug [21].
The semi-automated fluorometric microculture cytotox-
icity assay (FMCA), described in detail previously, was used
to assess drug sensitivity [22]. The method is based on
measurement of fluorescence generated from hydrolysis
of fluorescein diacetate (FDA) to fluorescein by cells with
intact plasma membranes. 384-well microplates (Nunc)
were prepared with 5 μl drug solution at 10 times the final
drug concentration using the pipetting robot BioMek 2000
(Beckman Coulter). The plates were then stored at −70°C
until further use.
Tumor cells from patient samples (5,000 cells/well for
the PC samples and 40,000 cells per well for leukemia
and MNCs) in 45 μl were seeded in the drug-prepared
384-well plates using the pipetting robot Precision 2000
(Bio-Tek Instruments Inc., Winooski, VT). Three columns
without drugs served as controls and one column with
medium only served as blank.
The culture plates were then incubated at 37°C in hu-
midified atmosphere containing 95% air and 5% CO2. After
72 h incubation, the culture medium was washed away and
50 μl/well of a physiological buffer containing 10 μg/ml of
the vital dye fluorescein diacetate (FDA) were added to
control, experimental and blank wells. After incubation for
30–45 min at 37°C, the fluorescence from each well was
read in a Fluoroscan 2 (Labsystems OY, Helsinki, Finland).
Quality control and quantification of results
Quality criteria for a successful assay were: ≥ 70% tumor
cells in the cell preparation prior to incubation and/or
on the assay day, a fluorescence signal in control cul-
tures of ≥ five times mean blank values, and a coefficient
of variation of cell survival in control cultures of ≤ 30%.
The results obtained by the viability indicator FDA are
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of the test expressed as a percentage of control cultures,
with blank values subtracted.
Concentration-response SI data were used to calcu-
late the 50% inhibitory concentrations, i.e. the drug
concentration producing a SI of 50%, (IC50). This was
done using non-linear regression to a standard sigmoidal
dose–response model in GraphPad Prism version 5 for
Mac (GraphPad Software, San Diego, CA, USA). Data
are presented as mean values ± SE for the number of
experiments/samples indicated.
Subgroup analysis of patients with peritoneal
carcinomatosis of colorectal origin
Histopathological data concerning lymph node positive
status, tumor grading, mucinous status, and signet cells
were collected from the pathological report of the primary
tumor resection. Date and cause of death, time to disease
progression, completeness of cytoreduction score (CC),
systemic chemotherapy prior to cytoreductive surgery and
use of adjuvant systemic chemotherapy after CRS and
IPC were also collected. Time to progression (TTP) was
selected as the clinically most relevant outcome measure
when investigating the correlation between ex vivo drug
sensitivity and clinical outcome.
Out of the 52 patients with PC from CRC, fifteen did
not receive IPC due to too advanced disease. The IPC in
the remaining 37 patients was intraoperative hyperthermic
IPC (HIPEC) or sequential postoperative intraperitoneal
chemotherapy (SPIC). HIPEC consisted of oxaliplatin
(360–460 mg/m2) administered intraperitoneally (ip) with
5-FU (400–500 mg/m2 plus folic acid) intravenously (iv)
in 12 patients. HIPEC with irinotecan and oxaliplatin
(360 mg/m2 of each drug) with 5-FU and folic acid iv
was used in 18 patients. SPIC with 5-FU (500 mg/m2)
infusion ip through a PORT á CATH (No. 21-2000-04,
SIMS Deltec, Inc., St Paul, MN, USA) at 4–6 week intervals
for 6 months postoperatively was used in 7 patients.
For systemic chemotherapy prior to the IPC (n = 39),
the interval between last administration and surgery
had to be at least 4 weeks. Adjuvant chemotherapy was
administered in 15 patients and the most common
regimen was oxaliplatin and 5-FU (n = 8).
There were 27 patients with a CC score of 0 receiving
IPC treatment and these were considered suitable for
assessment of the ex vivo – in vivo correlation. There
was missing data on recurrences in 4 patients and so the
analysis was possible in 23 patients. In line with previous
principles for correlation of ex vivo drug sensitivity to clin-
ical outcome [19], patients were scored as ex vivo ‘sensitive’
if they were treated with at least one drug with IC50 value
below the median for the whole study cohort and as
ex vivo ‘resistant” if they had received only drugs with all
IC50 values above the median.Statistics
Statistical inferences between several means were
performed by one-way ANOVA with Tukey’s multiple
comparison post-test of group means or, for comparison
of two means, by Student’s t-test. Cross-resistance between
selected drugs was analyzed by Spearman rank correlation.
The slope of the regression line was calculated with the
least squares method. Time to progression was compared
using the Kaplan-Meier curve’s median survival and the
log-rank test. For the CRC subgroup, the prognostic im-
portance of clinicopathological variables and ex vivo drug
sensitivity for TTP was assessed in a Cox regression model.
All univariate results with p < 0.05 were included in the
multivariable analysis using an all-effects function of both
forward and backward stepwise analysis. The level of sig-
nificance for all statistical tests was set to p < 0.05. The sta-
tistics software used in these analyses was STATISTICA
10.1 (StatSoft Inc, Tulsa, OK, USA).
Results
Patient samples
In total, 174 tumor samples from patients operated on
for PC, as detailed in Table 1, fulfilled the quality criteria
and were analyzed for drug sensitivity. The majority of
patients had PMP or CRC and the majority of samples
were from patients previously treated with chemotherapy.
The clinical characteristics for the CRC patient subgroup
are detailed in Table 2.
Drug sensitivity ex vivo
Samples from CRC, appendix cancer, and PMP generally
had higher IC50 values compared to the other groups
with the exception of 5-FU (Figure 1). Mesothelioma sam-
ples were surprisingly sensitive across the panel of drugs
similarly to ovarian cancer. As expected the leukemia
samples were mostly more sensitive or as sensitive as the
mesothelioma and ovarian cancer samples.
Based on the IC50 values and the ip concentrations of
each drug reached during IPC, as reported in the literature,
the ratios between the ip concentrations and the IC50 values
were calculated for each drug and PC diagnosis (Table 3).
High ratios would in theory be most beneficial. Across
all diagnoses, the clearly most beneficial ratio was observed
for oxaliplatin.
Some samples were essentially unaffected by the highest
drug concentrations tested whereas tumor cells from other
samples showed decreased viability even at the lowest con-
centration tested (Figure 2). The cross-resistance between
the different standard drugs investigated was modest to
high (Figure 3). In general this means that resistance to one
drug would also imply resistance to other drugs. On the
other hand, there are clearly many individual samples being
resistant to one but sensitive to the other drug, theoretically
supporting an individual choice of drugs for the IPC.
Table 2 Clinical characteristics of the CRC subgroup of
52 patients
Characteristics (n, except for age
in years and PCI in score units)
Colorectal cancer
Age – mean years (95% CI) 55 (51–59)





Oxaliplatin + irinotecan 18










Oxaliplatin/5-FU ± bev 30
Oxaliplatin/5-FU + cet 1
Oxaliplatin/capecitabine ± bev 4
Irinotecan/5-FU + bev 1
Capecitabine 1
5-FU alone 2
Adjuvant systemic chemo 15
Oxaliplatin/5-FU ± bev 8
Irinotecan/5-FU ± bev 2
Capecitabine 1
5-FU alone 1
Missing data on drug 3
Abbreviations: CRC colorectal cancer, PCI peritoneal cancer index, IPC
intraperitoneal chemotherapy, SPIC sequential postoperative intraperitoneal
chemotherapy, HIPEC hyperthermic intraperitoneal chemotherapy, CC
completeness of cytoreduction, Chemo chemotherapy, Bev bevacizumab, Cet
cetuximab.
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for the colorectal cancer subgroup
Table 4 details the mean IC50 values of each drug according
to different histopathological categories in the CRC
subgroup. The mucinous tumors generally had higher
IC50 values compared to those non-mucinous and this was
statistically significant or nearly significant for cisplatin
(30 vs. 14 μM, p = 0.05) and irinotecan (184 vs. 81 μM,
p = 0.07). Lymph node status at initial diagnosis, tumor
grade or signet ring cell type cancer did not consistently
affect drug sensitivity. There were essentially no differ-
ences in drug sensitivity between CRC PC samples frompatients previously exposed to cytotoxic drugs and those
being treatment naïve (Table 4).
Analysis of prognostic impact from histopathology
variables and drug sensitivity according to a Kaplan-Meier
survival analysis and a multivariable Cox regression model
are detailed in Table 5. After adjustment for various
prognostic factors in a multivariable model, sensitivity to
doxorubicin, synchronous PC and macroscopically radical
surgery were independently associated with longer TTP.
The results of the analysis of the direct relationships
between drug sensitivity ex vivo and clinical outcome in
individual CRC PC patients are detailed in Figure 4. The
Kaplan-Meier curves essentially overlap in the beginning
and do not differ statistically significantly. However, at three
years, there are three disease free patients in the sensitive
group and none in the resistant group. Longer follow-up
and more patients are needed for a conclusive analysis.
Discussion
The FMCA analysis has previously been shown to predict
drug efficacy in the clinic both on the diagnosis level and
on the individual patient level in hematological malignan-
cies and ovarian cancer [19,20,26]. Therefore, we expect
that the FMCA reports clinically relevant drug sensitivity
also in the current investigation. CRC, appendix cancer and
PMP were generally more resistant to standard cytotoxic
drugs than ovarian cancer and mesothelioma. However,
for docetaxel in PMP the IC50 value approached that of
leukemia. This is an interesting observation as docetaxel
also showed the lowest cross-resistance to other drugs.
Mesothelioma was surprisingly relatively sensitive across
all drugs tested. Cisplatin, the most common agent both
for systemic treatment and IPC in PC from mesothelioma
[27], is a good choice based on our findings. This is also in
line with the treatment results of CRS and IPC for meso-
thelioma, where the median survival ranges 34–96 months
with 5 year overall survival ranging 33-59%, which is better
than systemic chemotherapy results with median survival
ranging from 9 to 12.5 months [27]. Furthermore, abdom-
inal mesothelioma treated with cytoreductive surgery and
IPC appears to have better survival than CRC according
to a recent French study which is in line with the FMCA
results of greater drug sensitivity [28]. Notably, however,
given that the pattern of oxaliplatin activity is very similar
to that of cisplatin and the much more favorable concen-
tration ratio for oxaliplatin, use of this drug for IPC in
mesothelioma might produce even better results.
Despite having similar drug resistance patterns as CRC,
PMP has better survival than both CRC and mesothelioma.
The explanation for this is probably that the tumor biology
of PMP is more indolent compared with mesothelioma and
CRC regardless of the drug resistance pattern [29].
Appendix cancer was similar to CRC in drug sensitivity.
Thus, the current practice of treating these two entities
Figure 1 IC50 values for standard drugs in all peritoneal carcinoma samples investigated divided for the subtypes indicated. Results are
presented as means values + SE. Statistical inference was calculated with 1-way ANOVA with Dunnet’s post-test and with the colorectal cancer
samples as reference. The following panel of 8 drugs were investigated: A – Oxaliplatin, B – Cisplatin, C – Melphalan, D – 5FU, E – Mitomycin C,
F – Irinotecan, G – Docetaxel, H – Doxorubicin. *, ** and *** denotes P < 0.05, 0.001 and 0.0001 vs. colorectal samples, respectively. Absence of
asterixes means that no statistical differences compared to colorectal samples were observed.
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Table 3 Concentration ratios between IPC Cmax and ex vivo IC50 values
Cmax
† IC50 Cmax IC50 Cmax IC50 Cmax IC50 Cmax IC50 Cmax
CRC /IC50 Meso /IC50 PMP /IC50 App /IC50 Ova /IC50
μM CRC μM Meso μM PMP μM App μM Ova
Oxa [23]
573 μM‡ 31 18.5 12 47.7 29 19.9 35 16.4 15 38.2
Cis [24]
92 μM‡ 23 4.0 8 11.5 25 3.7 30 3.1 9 10.2
MMC [25]
30 μM‡ 20 1.5 5 6 16 1.9 19 1.6 8 3.7
Iri [17]
197 μM‡ 139 1.4 75 2.6 290 0.7 150 1.3 100 2.0
Dox [14]
17 μM‡ 2.8 6.1 0.9 19.1 2.0 8.6 2.3 7.5 1.2 14.3
† Maximum concentration achieved at the beginning of the IPC treatment.
‡ Dosage during HIPEC: oxa - 460 mg/m2, cis - 50 mg/m2, MMC - 35 mg/m2, Iri – 350 mg/m2, Dox – 15 mg/m2.
Abbreviations: IPC intraperitoneal chemotherapy, CRC colorectal cancer, Meso mesothelioma, PMP pseudomyxoma peritonei, App appendix cancer, Ova ovarian
cancer, Oxa oxaliplatin, Cis cisplatin, MMC mitomycin C, Iri irinotecan, Dox doxorubicin, N/A not available, HIPEC hyperthermic intraperitoneal chemotherapy.
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IPC in PC from CRC and appendix cancer, there are two
commonly used drugs, i.e. mitomycin C or oxaliplatin.
The results of the current study do not give a clear answer
to which drug is best but with mitomycin C one may only
reach intraperitoneal concentrations that approximate the
tumor cell IC50 values whereas with oxaliplatin, one might
reach 18 times greater a concentration ip. Thus, oxaliplatin
seems to be a more suitable drug for IPC. Interestingly,Figure 2 Tumor cell sensitivity, expressed as survival index (SI%) of th
drugs. The curves represent the non-linear regression lines calculated for a
points and illustrate together with the individual curves the great variability
B: mitomycin C, C: 5-fluorouracil, D: irinotecan.oxaliplatin appears to have the best Cmax IP/IC50 ratio for
the other PC diagnoses as well (Table 3).
The variability in ex vivo drug sensitivity in the CRC
subgroup was large, as also observed in a previous study
on tumor samples from PC [30], ranging from virtually
no to total cell death within the concentration range
tested. In principle, this argues, together with the obser-
vations of low cross-resistance in individual tumor sam-
ples, in favor of individualized choice of drug for IPC.e colorectal cancer samples for the indicated standard cytotoxic
ll individual samples included. The dots are individual patient data
in drug sensitivity between individual samples. Panel A: oxaliplatin,
Figure 3 Correlations between the cytotoxic activities (SI%) for the indicated pairs of standard cytotoxic drugs at concentrations
selected to provide optimal activity variation. The correlations are based on all peritoneal carcinoma samples investigated. The r denotes the
correlation coefficient and P the level of statistical significance. Panel A: correlation between cisplatin and oxaliplatin, B: 5-fluorouracil and
oxaliplatin, C: mitomycin C and oxaliplatin, D: irinotecan and oxaliplatin, E: docetaxel and oxaliplatin, F: doxorubicin and oxaliplatin, G: mitomycin C
and 5-fluorouracil, H: irinotecan and 5-fluorouracil.
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Table 4 Mean IC50 values of drugs grouped according to histopathological categories and previous treatment in the
CRC subgroup
Drugs Prior Chemotherapy Lymph node Mucinous Tumour differentiation Signet cell
n=49† Yes No Pos Neg Yes No Poor Moderate Well Yes No
n=39 n=10 n=37 n=12 n=29 n=20 n=19 n=24 n=6 n=6 n=43
Oxa 31.7 30.1 (0.9) 31.0 32.4 (0.9) 36.9 22.6 (0.1) 34.7 23.9 (0.5) 35.3 29.1 31.6 (0.9)
Cis 21.6 26.2 (0.6) 20.1 23.8 (0.9) 29.7 13.6 (0.05) 23.3 17.0 (0.4) 32.8 13.7 24.7 (0.4)
Mel 53.3 52.2 (0.9) 56.1 53.1 (0.8) 52.4 53.8 (0.9) 49.1 53.3 (0.9) 54.8 44.2 52.9 (0.5)
5-FU 539.5 475.4 (0.6) 497.5 604.9 (0.4) 542.1 455.5 (0.4) 521.5 426.6 (0.3) 689.9 490.4 519.2 (0.9)
MMC 19.1 22.5 (0.7) 23.3 12.0 (0.3) 24.6 14.2 (0.2) 12.8 20.5 (0.4) 29.4 8.68 21.2 (0.3)
Iri 131.7 163.1 (0.6) 153.3 111.2 (0.5) 183.9 81.1 (0.07) 122.0 163.5 (0.8) 129.2 84.4 151.6 (0.5)
Doce 15.0 21.5 (0.3) 18.5 13.8 (0.4) 17.2 16.6 (0.9) 16.9 17.9 (0.8) 12.4 23.5 14.4 (0.1)
Dox 2.80 2.98 (0.9) 3.34 1.59 (0.1) 2.96 2.78 (0.9) 1.74 3.51 (0.3) 2.86 1.20 2.96 (0.3)
Numbers in parentheses represent p-values from a Student t-test with the exception of tumor grading which was calculated with a one-way ANOVA.
† Missing histopathological data in 3 patients.
Abbreviations: Pos positive, Neg negative, Oxa oxaliplatin, Cis cisplatin, 5-FU 5-fluorouracil, MMC mitomycin C, Iri irinotecan, Doce docetaxel, Dox doxorubicin.
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drug sensitivity measurements prior to CRS and IPC.
Although this would complicate the logistics, it would be
feasible since tumor tissue is accessible by laparoscopy and
the assay time is 3 days. However, well designed clinical
trials evaluating clinical benefit from ex vivo drug sensitivity
testing are unfortunately few, sub-optimally designed and
do not allow firm conclusions [31].
In PC from CRC, mucinous tumors were generally less
drug sensitive than non-mucinous tumors. This is in line
with previous results that mucinous CRC is less responsiveTable 5 Univariate and multivariable Cox regression model fo
values (above or below the median value) and clinicopatholo
n = 47 Median TTP Log-rank
Months p
Treated vs. untreated 10 vs. 5 0.06
Oxaliplatin † 5 vs. 5 0.8
Cisplatin † 5 vs. 5 0.8
Melphalan † 12 vs. 7 0.8
5-FU † 6 vs. 5 0.7
Mitomycin C † 12 vs. 4 0.2
Irinotecan † 5 vs. 5 0.9
Docetaxel † 10 vs. 4 0.6
Doxorubicin † 12 vs. 1 0.008
Synch. vs. Metach. 9 vs. 4 0.05
Vasc./neural vs. not 2 vs. 10 0.05
Mucinous vs. not 9 vs. 5 0.12
Lymph node + vs. not 6 vs. 7 0.9
CC0 vs. CC 1-3 18 vs. 4 0.002
There was missing data concerning TTP in 5 patients.
† Below vs. above the median IC50 value. Low IC50 indicates better sensitivity.
Abbreviations: TTP time to progression, CRC colorectal cancer, Synch synchronous, m
of cytoreduction.to systemic chemotherapy than non-mucinous CRC [32].
Interestingly, oxaliplatin and 5-FU were essentially equally
active in chemotherapy naïve and previously treated pa-
tients. This may be due to patient selection; i.e. previously
treated patients suitable for CRS and IPC are those without
drug resistant tumors. Still, there is no support for selection
of drugs for IPC based on prior treatment status. The same
conclusion holds for lymph node status, tumor grade and
presence of signet ring cells.
Doxorubicin drug sensitivity was found to be an in-
dependent prognostic factor for TTP. This might wellr TTP according to dichotomised IC50 drug sensitivity

















etach metachronous, vasc/neural vascular or neural invasion, CC completeness
Figure 4 Kaplan-Meier curve between a more sensitive group and a more resistant group as defined as above or below the median value.
Patients receiving IPC with at least one sensitive drug were included in the sensitive group (n = 15) and those receiving only resistant drugs were
included in the resistant group (n = 8). Only CC 0 patients from the colorectal cancer group were included in the analysis. p = 0.4.
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drug sensitivity could indicate CRC tumor cell susceptibility
to cancer drugs or that sensitivity to doxorubicin is as-
sociated with less aggressive tumor biology.
To support the conclusions and proposals above on
the implications of our findings for the use of IPC for PC in
the clinic and the role of ex vivo drug sensitivity testing,
one would like to know, firstly, that IPC adds benefit to
CRS and, secondly, that the ex vivo drug sensitivity data
correlates to clinical outcome in patients undergoing IPC.
Unfortunately, there is insufficient support for both of these
aspects. Support for the benefit from the IPC when added
to CRS only derives from one randomized trial in PC from
gastric cancer [9], randomized trials in ovarian cancer [8],
and from a rodent CRC PC model [11]. In PC from CRC,
there was one randomized trial started to elucidate this
issue but stopped prematurely after inclusion of 35 patients
due to poor patient accrual [33]. There was no trend for
benefit from IPC. There is, thus, need for a controlled
trial to elucidate this important issue. One such study
for CRC (Prodige 7) in France has soon completed its
recruitment process.
In the CRC subset, the analysis of the relationship
between ex vivo activity of the drugs given to the patient
and the clinical outcome in terms of TTP showed no
difference between ‘sensitive’ and ‘resistant’ patients in
the short term; but unfortunately, the analysis suffers from
major methodological problems related to the limited andheterogeneous data available making the results essentially
inconclusive. The number of analyzable patients was a
mere 23 (15 vs. 8, Figure 4) as the remaining patients
were either open-and-close patients or did not reach
complete cytoreduction during the surgery. Furthermore,
heterogeneity of drug regimens administered compounded
the problem of predictive analysis. A greater number of
patients with sufficient follow-up are needed to make a
reasonable ex vivo – clinical outcome analysis, which is
of importance considering the possible long term effect
indicated in Figure 4.
On the other hand, the lack of relationship between
the ex vivo drug sensitivity and clinical outcome might
be true. This could be the case if the FMCA does not
report clinically relevant information. The assay differs
from the in vivo situation in several aspects related to
both pharmacokinetics and pharmacodynamics. Also
relevant, is the dwell time that is significantly longer
than in the IPC situation. This may have implications for
cell-cycle dependant drugs. However, these differences are
more or less inherent in all disease and treatment models,
and this will reasonably mean that an ex vivo test like the
FMCA will never show a perfect correlation to the clinical
outcome. Other reasons for the possible lack of relation-
ship between drug sensitivity and clinical outcome might
be that IPC adds no benefit at all to CRS or, alternatively,
that the drug concentrations reached during IPC are suffi-
ciently high to overcome drug resistance. Taken together,
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when it comes to adding IPC to CRS for treatment of PC.
Conclusions
Drug-sensitivity varies considerably between PC diagnoses
and individual patients arguing for individualized therapy
in IPC rather than standard diagnosis-specific therapy.
However, in the current paradigm of treatment according
to diagnosis, oxaliplatin is seemingly the preferred drug for
IPC from a drug sensitivity and concentration perspective.
In the CRC subset, analysis of correlation between ex vivo
drug sensitivity and TTP was inconclusive due to the
heterogeneous nature of the data.
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